Egnite utilizes artificial intelligence-driven algorithms to analyze real-world cardiovascular data, providing healthcare professionals with actionable insights for patient management. The platform enhances decision-making for cardiovascular care, aiming to improve outcomes for patients across the United States.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiovascular disease management relies on accurate analysis of patient data to inform clinical decisions; however, traditional methods often struggle to efficiently process and interpret the large volumes of real-world data, leading to potential delays in diagnosis and treatment. This can result in suboptimal outcomes for patients with conditions like valve disease, heart failure, and atrial fibrillation.
Solution
Egnite provides a digital health platform that leverages artificial intelligence to analyze real-world cardiovascular data, offering healthcare professionals actionable insights to improve patient care. The CardioCare platform uses AI-driven algorithms to identify patterns and predict outcomes, enabling clinicians to make more informed decisions regarding evaluation, management, and treatment strategies. By integrating data from various sources, Egnite aims to enhance the role of data in critical decisions, ultimately improving cardiovascular health outcomes. The platform supports solutions across valve disease, heart failure, atrial fibrillation, and clinical trials.
Target Audience
Egnite's primary customers include health systems, hospitals, and life sciences organizations focused on improving cardiovascular care and outcomes. The platform is designed for health professionals, including cardiologists and cardiovascular administrators.
Features
- AI-driven algorithms for analyzing cardiovascular data from diverse sources
- Business intelligence tools to elevate the role of data in clinical decision-making
- CardioCare platform designed for progressive cardiovascular centers
- Solutions for valve disease, heart failure, atrial fibrillation, and clinical trials
- Identification of potential candidates for research trials
- Benchmarking capabilities to assess performance against AHA/ACC guidelines
- Integration of data from 34,000+ severe AS patient records